Caribou Biosciences, Inc. stock is up 35.65% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November. 0% of analysts rate it a buy.
Caribou Biosciences, Inc. engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010 and CB-011, which are in phase 1 clinical trials to treat relapsed or refractory B cell non-Hodgkin lymphoma.